Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

SEAGEN INC.

(SGEN)
  Rapport
Cours en différé. Temps Différé Nasdaq - 30/11 22:00:01
160 USD   -3.21%
15/11VENTE PAR UN INITIÉ : Seagen
MT
09/11SEAGEN INC. : Wolfe Research révise son opinion et passe à neutre
ZM
08/11VENTE PAR UN INITIÉ : Seagen
MT
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur SEAGEN INC.
24/11SEAGEN : Material Event - Form 8-K
24/11SEAGEN INC. : Other Events (form 8-K)
19/11Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cance..
19/11Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cance..
15/11INSIDER SELL : Seagen
09/11Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual M..
09/11Seagen to Highlight Two Novel Antibody-Drug Conjugates at the SITC 36th Annual Meeting
08/11INSIDER SELL : Seagen
04/11Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the ..
04/11Seagen Inc. to Highlight Multiple ADCETRIS? (brentuximab vedotin) Data Presentations at..
03/11INSIDER SELL : Seagen
29/10Q3 2021 Earnings Call Corrected Transcript
28/10SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
28/10Seagen Swings to Q3 Loss as Revenue Drops; Shares Rise After Hours
28/10Seagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
28/10SEATTLE GENETICS : Q3 Earnings Snapshot
28/10Seagen Reports Third Quarter 2021 Financial Results - Form 8-K
28/10SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
28/10Seagen Reports Third Quarter 2021 Financial Results
28/10Earnings Flash (SGEN) SEAGEN Reports Q3 Revenue $424.1M, vs. Street Est of $384.8M
28/10EARNINGS REACTION HISTORY : Seagen Inc, 57.1% Follow-Through Indicator, 6.3% Sensitive
13/10Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
12/10SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
12/10Seagen Inc. and Astellas Pharma Inc. Complete Enrollment in EV-103 Trial Cohort K Combi..
07/10SEAGEN : to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Re..
01/10Autumn cold snap
01/10ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
28/09SEAGEN : Completes Patient Enrollment for Phase 2 Trial of Tukysa to Treat Metastatic Colo..
28/09ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
28/09SEAGEN : Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (..
28/09Seagen Inc. Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUK..
27/09SEAGEN : Urothelial Cancer Drug Padcev Gets Japanese Regulator's Approval
27/09Japan’s MHLW Approves Astellas Pharma Inc. and Seagen Inc.'s PADCEV (enfortumab vedotin..
21/09SEAGEN : = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS..
21/09SEAGEN INC. : Completion of Acquisition or Disposition of Assets, Financial Statements and..
21/09SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
21/09SEAGEN : Presentation (opens in new window)
21/09SEAGEN : and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-..
21/09U.S. Food and Drug Administration Grants Approval to TIVDAK
21/09SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
21/09SEAGEN : Genmab Win Accelerated US FDA Nod For Cervical Cancer Drug
21/09Didi Co-Founder Plans Exit as Beijing Crackdown Intensifies
20/09SEAGEN : Genmab Win US FDA Accelerated Approval of Tivdak in Previously Treated Recurrent,..
20/09SEAGEN : to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss T..
20/09SEAGEN : and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin..
20/09Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Ved..
20/09Didi global co-founder jean liu has told close associates she intends to leave - source..
20/09SEAGEN : Genmab's Cervical Cancer Combos Show Anti-Tumor Activity In Phase I Study
19/09Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Ved..
16/09China's biotech sector comes of age with big licensing deals, global ambitions
09/09SEAGEN : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
08/09SEAGEN : to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2..
06/09SOFTBANK : Ciudad de Pekín niega estar aconsejando a compañías que inviertan en Didi
06/09SOFTBANK : Beijing city denies it is advising companies to invest in Didi
04/09Didi denies reports that Beijing city is coordinating companies to invest in it
03/09Beijing city looks to take Didi under state control, Bloomberg News reports
03/09Didi could be taken under state control - report
17/08SEAGEN : Insider at Seagen (SGEN) Makes Significant Sale of Stock
14/08INSIDER TRENDS : 90-Day Insider Buying Trend Scaled Back with Sale of Seagen Shares
12/08Didi niega cambios en la dirección en plena investigación sobre ciberseguridad
10/08REMEGEN : Strikes $2.6 Billion Cancer Drug Licensing Deal with Nasdaq-listed Seagen
09/08SEAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
09/08SEAGEN : and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for..
09/08Seagen Inc. and RemeGen Co., Ltd. Announces Exclusive Worldwide License and Co-Developm..
29/07SEAGEN : Q2 Loss Widens Amid Higher Revenue, Reaffirms Guidance -- Stock Up 2% After-Hours
29/07SEAGEN : Reports Second Quarter 2021 Financial Results (Form 8-K)
29/07SEAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat..
29/07Seagen Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
29/07SEATTLE GENETICS : Q2 Earnings Snapshot
29/07SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
29/07SEAGEN : Earnings Flash (SGEN) SEAGEN Reports Q2 Revenue $388.5M, vs. Street Est of $357.7..
29/07SEAGEN : Reports Second Quarter 2021 Financial Results
29/07Seagen Inc. Provides Earnings Guidance for 2021
29/07EARNINGS REACTION HISTORY : Seagen Inc, 50.0% Follow-Through Indicator, 7.3% Sensitive
15/07SEAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
1  2  3  4  5  6  7  8  9  10Suiv.